Influence of Medication on Flare Up and Infection After Elective Orthopedic Surgery in Rheumatoid Arthritis Patient – A Narrative Review
Downloads
Background: Orthopedic Surgery in Rheumatoid Arthritis (RA) patients is still controversial between orthopedic surgeons and rheumatologists, mainly due to infection and disease flares. The incidence of postoperative infections may be high due to the immunosuppressive effect of RA medication. Conversely, discontinuance of antirheumatic agents increases the possibility of a disease flare. The objective of our review is to assess the influence of drugs on both incidences.
Literature Review: There were 13 studies included in this review. Methotrexate (MTX) is the most common csDMARD option among the included studies. One retrospective study that the incidence of flares tends to be higher among the group of patients who received MTX therapy and stopped more than one week before surgery than the group who did not stop. The use of MTX doses of 5 to 10 mg/week did not show an association with infection or flare incidence. On the use of bDMARD, 37.0% of patients had higher surgical site infection (SSI). Specifically, Tumor Necrosis Factor-alpha (TNF-α) inhibitors significantly (OR: 9.5, 95% CI: 1.0-88.8) increase the incidence of postoperative infections in standard-dose and high-dose, but not significantly in the rate of flares.
Summary: csDMARD is recommended for continuous therapy, whereas for bDMARD, although it is recommended for withholding in the perioperative period, the results of the study did not show significant differences. The ideal dosage of medication is by the basic properties of the drug. In comparison, the incidence of flares and infections was significantly higher in biologic than csDMARD.
Tateiwa D, Yoshikawa H, Kaito T. Cartilage and Bone Destruction in Arthritis: Pathogenesis and Treatment Strategy: A Literature Review. Cells 2019; 8(8): 818.
Bullock J, Rizvi SAA, Saleh AM, et al. Rheumatoid Arthritis: A Brief Overview of the Treatment. Med Princ Pract 2018; 27: 501–7.
Yeganeh MH, Kheir MM, Shahi A, Parvizi J. Rheumatoid Arthritis, Disease Modifying Agents, and Periprosthetic Joint Infection: What Does a Joint Surgeon Need to Know? J Arthroplasty 2018; 33: 1258-64.
Young BL, Watson SL, Perez JL, et al. Trends in joint replacement surgery in patients with rheumatoid arthritis. J Rheumatol 2018; 45: 158–64.
Danoff JR, Moss G, Liabaud B, Geller JA. Total knee arthroplasty considerations in rheumatoid arthritis. Autoimmune Dis 2013; 2013: 185340.
LoVerde ZJ, Mandl LA, Johnson BK, Figgie MP, Boettner F, Lee YY, et al. Rheumatoid arthritis does not increase risk of short-term adverse events after total knee arthroplasty: A retrospective case-control study. J Rheumatol 2015; 42: 1123–30.
Harb MA, Solow M, Newman JM, Sodhi N, Pivec R, George J, et al. Have the Annual Trends of Total Knee Arthroplasty in Rheumatoid Arthritis Patients Changed? J Knee Surg 2018; 31: 841–5.
Cordtz RL, Zobbe K, Højgaard P, Kristensen LE, Overgaard S, Odgaard A, et al. Predictors of revision, prosthetic joint infection and mortality following total hip or total knee arthroplasty in patients with rheumatoid arthritis: A nationwide cohort study using Danish healthcare registers. Ann Rheum Dis 2018; 77: 281–8.
Franco AS, Iuamoto LR, Pereira RMR. Perioperative management of drugs commonly used in patients with rheumatic diseases: a review. Clinics (Sao Paulo) 2017; 72: 386–90.
Goodman SM, Springer B, Guyatt G, Abdel MP, Dasa V, George M, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Rheumatol 2017; 69: 1538–51.
Gualtierotti R, Parisi M, Ingegnoli F. Perioperative management of patients with inflammatory rheumatic diseases undergoing major orthopaedic surgery: A practical overview. Adv Ther 2018; 35: 439–56.
Momohara S, Kawakami K, Iwamoto T, Yano K, Sakuma Y, Hiroshima R, et al. Prosthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs. Mod Rheumatol 2011; 21: 469–75.
Baker JF, George MD. Prevention of Infection in the Perioperative Setting in Patients with Rheumatic Disease Treated with Immunosuppression. Curr Rheumatol Rep 2019;21(5):17
George MD and Baker JF. Perioperative management of immunosuppression in patients with rheumatoid arthritis. Curr Opin Rheumatol. 2019; 31: 300–6.
Goodman SM. Rheumatoid arthritis: Perioperative management of biologics and DMARDs. Semin Arthritis Rheum 2015; 44: 627–32.
Keith MP. Perspectives on rheumatoid arthritis for the orthopedic surgeon: overview of non-tumor necrosis factor biologic drugs and perioperative management. Am J Orthop (Belle Mead NJ) 2011; 40: E272-5.
Fleury G, Mania S, Hannouche D, Gabay C. The perioperative use of synthetic and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Swiss Med Wkly 2017; 147: w14563.
George MD, Baker JF, Winthrop K, Alemao E, Chen L, Connolly S, et al. Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty: A Cohort Study. Ann Intern Med 2019;170:825–36.
Hayashi S, Sakai Y, Hashimoto S, Takayama K, Matsumoto T, Takebe K, et al. Risk factors for late deep infection after total hip arthroplasty in patients with rheumatoid arthritis. Acta Reumatol Port 2017;42:150–4.
Johnson BK, Goodman SM, Alexiades MM, Figgie MP, Demmer RT, Mandl LA. Patterns and associated risk of perioperative use of anti-tumor necrosis factor in patients with rheumatoid arthritis undergoing total knee replacement. J Rheumatol 2013;40:617–23.
Kubota A, Nakamura T, Miyazaki Y, Sekiguchi M, Suguro T. Perioperative complications in elective surgery in patients with rheumatoid arthritis treated with biologics. Mod Rheumatol 2012;22:844–8.
Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 2001;60:214–7.
Murata K, Yasuda T, Ito H, oshida M, Shimizu M, Nakamura T. Lack of increase in postoperative complications with low-dose methotrexate therapy in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Mod Rheumatol 2006;16:14–9.
Jain A, Witbreuk M, Ball C, Nanchahal J. Influence of steroids and methotrexate on wound complications after elective rheumatoid hand and wrist surgery. J Hand Surg Am 2002;27:449–55.
Goodman SM and Paget S. Perioperative Drug Safety in Patients with Rheumatoid Arthritis. Rheum Dis Clin North Am 2012;38:747–59.
Pountos I and Giannoudis P V. Effect of methotrexate on bone and wound healing. Expert Opin Drug Saf 2017;16:535–45.
Wolfe J, Wolfe J, Visser HJ. Perioperative Management of the Rheumatoid Patient. Clin Podiatr Med Surg 2019;36:115–30.
Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020; 685–99.
Jin J, Chang Y, Wei W. Clinical application and evaluation of anti-TNF-alpha agents for the treatment of rheumatoid arthritis. Acta Pharmacol Sin 2010;31:1133–40.
Goodman SM, Bykerk VP, DiCarlo E, et al. Flares in patients with rheumatoid arthritis after total hip and total knee arthroplasty: Rates, characteristics, and risk factors. J Rheumatol 2018;45:604–11.
Yano K, Ikari K, Inoue E, Tokita A, Sakuma Y, Hiroshima R, et al. Effect of total knee arthroplasty on disease activity in patients with established rheumatoid arthritis: 3-year follow-up results of combined medical therapy and surgical intervention. Mod Rheumatol 2010;20:452–7.
Kawakami K, Ikari K, Kawamura K, Tsukahara S, Iwamoto T, Yano K, et al. Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-α blockers: Perioperative interruption of tumour necrosis factor-a blockers decreases complications? Rheumatology 2010;49:341-7.
Compagnoni R, Gualtierotti R, Randelli P. Total Joint Arthroplasty in Patients with Inflammatory Rheumatic Diseases. Adv Ther 2018;35:1133–9.
Nash P and Nicholls D. Perceptions of methotrexate use in rheumatoid arthritis by rheumatologists and their patients: AN Australian survey study. Int J Rheum Dis 2013;16:652–61.
Copyright (c) 2020 JOINTS (Journal Orthopaedi and Traumatology Surabaya)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
- The author acknowledges that the copyright of the article is transferred to the Journal of Orthopaedi and Traumatology Surabaya (JOINTS), whilst the author retains the moral right to the publication.
- The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution-Non Commercial-Share Alike 4.0 International License (CC BY-NC-SA).
- All published manuscripts, whether in print or electronic form, are open access for educational, research, library purposes, and non-commercial uses. In addition to the aims mentioned above, the editorial board is not liable for any potential violations of copyright laws.
- The form to submit the manuscript's authenticity and copyright statement can be downloaded here.
Journal of Orthopaedi and Traumatology Surabaya (JOINTS) is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 International License.
Journal Orthopaedi and Traumatology Surabaya (JOINTS) (